Desmoid tumors are rare growths in the body’s connective tissue that, while not cancerous, can grow aggressively and cause significant health challenges. Treatment approaches focus on controlling tumor growth, managing symptoms like pain and limited movement, and improving the ability to carry out daily activities and maintain quality of life.

Understanding Treatment Goals for Desmoid Tumors

When you’re diagnosed with a desmoid tumor, the path forward depends on many factors specific to your situation. These noncancerous but locally aggressive growths arise from connective tissue—the material that holds your bones, muscles, and organs together—and they require thoughtful, individualized care plans.^[1]

Treatment decisions for desmoid tumors are not one-size-fits-all. Your care team will consider where the tumor is located in your body, how fast it appears to be growing, whether it’s causing symptoms, and how it might affect nearby organs or blood vessels. Because desmoid tumors behave unpredictably—some grow slowly or even shrink on their own, while others expand quickly—your doctor may recommend different approaches at different times.^[2][3]

The main goals of treatment are to slow or stop tumor growth, relieve pain and other symptoms, preserve function in affected areas of the body, and prevent the tumor from damaging vital structures. Since desmoid tumors don’t spread to distant parts of the body like cancers do, treatment focuses on local control rather than systemic spread.^[1]

Medical societies and expert groups have developed guidelines to help doctors make treatment recommendations. These include standard treatments that have been used for years, as well as newer therapies being tested in clinical research. An international team of specialists published comprehensive guidelines in 2020 to standardize how doctors approach desmoid tumor care, and these guidelines continue to evolve as researchers learn more.^[14]

Because desmoid tumors are rare—affecting only about two to four people per million each year—it’s important to work with specialists who have experience treating this condition. Many patients benefit from care at major medical centers where teams of doctors from different specialties collaborate on treatment plans.^[7][19]

Standard Treatment Approaches

Active Surveillance: Watching and Waiting

One of the most important discoveries in desmoid tumor care is that not all tumors need immediate treatment. In fact, active surveillance—carefully monitoring the tumor without active intervention—has become the recommended first approach for many patients, especially those without symptoms or whose tumors are not growing quickly.^[14][15]

This might seem counterintuitive when you have a tumor, but research shows that approximately 20 percent of desmoid tumors can shrink or disappear on their own without any treatment at all. This spontaneous improvement is called spontaneous regression. During active surveillance, you’ll have regular imaging tests—typically every few months—so your doctor can track whether the tumor is staying stable, shrinking, or growing.^[7][11]

The benefit of active surveillance is that it avoids the risks and side effects of treatments you might not need. Surgery, radiation, and medications all carry potential complications, so if your tumor is not causing problems, waiting can be the wisest choice. However, if scans show the tumor is growing or if you develop symptoms, your care team can shift to a more active treatment strategy.^[14]

Surgical Treatment

Surgery was once considered the standard treatment for desmoid tumors, but medical thinking has changed significantly. While surgery can sometimes remove the tumor completely, these growths have a strong tendency to come back even after they appear to be fully removed. Studies show recurrence rates ranging from 24 percent to 77 percent after surgical removal, depending on the tumor’s location and other factors.^[15][4]

Even when surgeons achieve what are called “clean margins”—meaning they remove all visible tumor plus a border of healthy tissue—desmoid tumors can still return. Various studies report recurrence rates of 15 percent to 30 percent even after complete surgical removal, with most recurrences happening within five years.^[15]

Current medical guidelines recommend surgery primarily for certain specific situations. For tumors in the abdominal wall that haven’t responded to observation, surgery may be appropriate if a multidisciplinary team of specialists agrees it’s the best option. However, for tumors in other locations, or for tumors associated with familial conditions, medical therapies are generally recommended as the second-line treatment when observation is no longer appropriate.^[14][15]

The decision about surgery also depends on what the operation might involve. Sometimes removing a desmoid tumor would require very extensive surgery that could affect your ability to use an arm or leg, or could require removing important structures. In these cases, the risks of surgery may outweigh the potential benefits, especially given the high chance of the tumor returning.^[11]

Radiation Therapy

Radiation therapy uses high-energy beams to damage tumor cells and stop their growth. For desmoid tumors, radiation can be used in several ways: after surgery to treat any remaining tumor cells, before surgery to shrink the tumor, or as the main treatment instead of surgery.^[11]

Radiation therapy may be particularly useful for tumors that can’t be safely removed with surgery because of their location near vital organs or blood vessels. However, there’s an important consideration with radiation: it can potentially cause other health problems years later, including the development of different cancers. This is especially concerning for younger patients who have many years ahead of them.^[3]

Because of these long-term risks, doctors carefully weigh whether radiation therapy is appropriate for each individual patient. It’s important to discuss both the potential benefits and future risks with your care team. Some medical centers use advanced forms of radiation therapy that can more precisely target the tumor while sparing surrounding healthy tissue.^[11]

Medical Therapies

Various medications have been used to treat desmoid tumors, though until recently, none were specifically approved for this condition. Medical therapies are recommended as first-line treatment for progressive or symptomatic tumors at most body sites, and for all familial desmoid tumors that fail observation.^[14][15]

Nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used for pain and inflammation, have shown some benefit in desmoid tumor treatment. These include medications you might recognize, like sulindac or celecoxib. They may work by reducing inflammation signals that contribute to tumor growth. NSAIDs are generally well tolerated, though long-term use can cause stomach upset, increase bleeding risk, or affect kidney function.^[14]

Antiestrogen medications have also been used because some evidence suggests hormones, particularly estrogen, may influence desmoid tumor growth. This connection is supported by the fact that women are more likely to develop these tumors, and they sometimes appear during or shortly after pregnancy when estrogen levels are high. Medications like tamoxifen, which blocks estrogen receptors, have been tried with variable results. Side effects can include hot flashes, mood changes, and increased risk of blood clots.^[12][2]

Chemotherapy regimens developed for sarcomas and other cancers have been adapted for desmoid tumors. These include combinations like doxorubicin with dacarbazine, or methotrexate with vinblastine. While these medications can shrink tumors, they also come with more significant side effects including nausea, fatigue, hair loss, increased infection risk, and effects on blood cell counts. Chemotherapy is typically reserved for more aggressive or symptomatic tumors that haven’t responded to other approaches.^[3][12]

Tyrosine kinase inhibitors represent a more targeted approach. These medications block specific molecular signals that tumor cells use to grow. Drugs like sorafenib and pazopanib have shown promise in treating desmoid tumors. They work by interfering with proteins involved in cell growth and blood vessel formation. Side effects can include skin changes, diarrhea, high blood pressure, and fatigue.^[12][16]

Ablation and Other Local Treatments

Some treatment centers offer techniques that destroy tumor tissue without traditional surgery. Cryoablation uses extreme cold to freeze and kill tumor cells. Radiofrequency ablation uses heat generated by radio waves. High-intensity focused ultrasound uses sound waves to heat and destroy targeted tissue. These approaches can be considered as alternatives to medical therapies for selected patients, depending on tumor location and size.^[14][15]

Pain Management

Controlling pain is a critical part of desmoid tumor treatment, regardless of what approach is taken for the tumor itself. Pain doesn’t just cause physical discomfort—it can affect every aspect of life, from sleep to mood to ability to work and care for family. Medical guidelines emphasize that pain control is paramount to improve quality of life, independent of the treatment used against the tumor itself.^[14]

Pain management strategies may include NSAIDs, other pain medications, physical therapy, mindfulness practices, and complementary treatments like acupuncture. Your healthcare team should work with you to find an approach that keeps your pain at a manageable level so you can continue to participate in daily activities.^[17]

Treatment in Clinical Trials

Breakthrough FDA-Approved Therapy

In November 2023, the United States Food and Drug Administration approved the first medication specifically for desmoid tumors: nirogacestat, marketed under the brand name Ogsiveo. This approval represented a major milestone for patients and doctors, as it was the first drug to receive official authorization for treating this rare condition.^[12][13]

Nirogacestat belongs to a class of medications called gamma-secretase inhibitors. Gamma-secretase is an enzyme—a protein that helps carry out chemical reactions in cells—that cleaves or cuts apart other proteins. One of these proteins is called Notch, which plays a role in activating pathways that contribute to desmoid tumor growth. By blocking gamma-secretase, nirogacestat prevents these growth signals from being activated.^[12]

The drug is indicated specifically for adults with progressive desmoid tumors who need systemic (whole-body) treatment. This means it’s for patients whose tumors are growing or causing symptoms that require medical intervention beyond just observation.^[12]

The DeFi Trial: Testing Nirogacestat

The FDA approval of nirogacestat was based on results from a Phase 3 clinical trial called DeFi. This was a rigorous study in which 142 patients with desmoid tumors were randomly assigned to receive either nirogacestat or a placebo (an inactive pill that looked identical but contained no active drug). Neither the patients nor their doctors knew who was receiving which treatment until the study ended—this design, called a double-blind study, ensures the results are objective.^[12]

Seventy patients received nirogacestat while 72 received placebo. The study measured progression-free survival—how long patients went without their tumor growing or getting worse. The results were striking: patients taking nirogacestat had significantly better progression-free survival. At two years, 76 percent of patients on nirogacestat were event-free, compared to 44 percent of those on placebo.^[12]

Even more impressive were the response rates. Forty-one percent of patients taking nirogacestat had an objective response—meaning their tumors measurably shrank—compared to only 8 percent in the placebo group. Some patients experienced complete responses, where their tumors disappeared entirely: 7 percent of nirogacestat patients achieved this outcome, while none of the placebo patients did. The median time to see a response was about 5.6 months for the nirogacestat group.^[12][13]

Other Investigational Therapies

Beyond nirogacestat, researchers continue to explore other therapeutic approaches for desmoid tumors. Understanding the molecular biology of these growths has opened doors to developing targeted treatments that interfere with specific pathways involved in tumor growth.^[16]

Scientists have discovered that most desmoid tumors have mutations in genes called CTNNB1 or APC. These mutations affect a protein called beta-catenin, which accumulates in cells and sends signals that promote excessive cell growth. CTNNB1 mutations account for about 90 percent of sporadic (non-inherited) desmoid tumors, while APC mutations cause tumors associated with familial adenomatous polyposis, an inherited condition.^[9]

This genetic understanding has led researchers to develop drugs that target the molecular pathways affected by these mutations. Various pharmaceutical companies and research institutions are testing molecules that can block different steps in the growth signaling cascade. These investigational drugs are studied in phases:^[16]

Phase I trials are the earliest studies in humans. They focus primarily on safety—determining what dose of a new drug can be given without causing unacceptable side effects. These trials usually involve small numbers of patients and carefully monitor for any adverse reactions.

Phase II trials expand to larger groups of patients and focus on whether the drug appears to be effective. Researchers measure outcomes like tumor shrinkage or time until tumor growth. They continue to monitor safety as well. If a drug shows promise in Phase II, it moves forward.

Phase III trials are large studies that compare the new treatment to current standard treatments or to placebo. The DeFi trial that led to nirogacestat approval was a Phase III study. These trials provide the strongest evidence about whether a new treatment works and is safe enough for widespread use.

Where Trials Are Conducted

Clinical trials for desmoid tumors are conducted at specialized medical centers around the world. In the United States, many trials take place at major cancer centers affiliated with universities or as part of research networks. Trials are also conducted in Europe and other regions where sarcoma specialists work.^[3]

Not every patient is eligible for every trial. Studies have specific criteria about tumor location, size, whether the patient has received prior treatments, and other health factors. Your medical team can help you understand whether any current trials might be appropriate for your situation. Organizations like the Desmoid Tumor Research Foundation and the Sarcoma Alliance for Research through Collaboration maintain information about ongoing studies.^[19]

Looking Toward the Future

The approval of nirogacestat represents just the beginning of targeted therapy development for desmoid tumors. Researchers are investigating other molecular targets and treatment approaches. Some studies are exploring whether combinations of drugs might work better than single agents. Others are examining whether drugs originally developed for other conditions might be repurposed for desmoid tumors.^[16]

Gene therapy approaches, which would correct or compensate for the genetic mutations causing desmoid tumors, remain in early research stages but represent an exciting future direction. Immunotherapy strategies that help the body’s immune system recognize and attack tumor cells are also being explored, though these are less advanced for desmoid tumors compared to other cancers.^[16]

Most Common Treatment Methods

• Active Surveillance
  • Monitoring tumor with regular imaging tests every few months
  • Recommended first approach for asymptomatic tumors not rapidly growing
  • About 20 percent of tumors can shrink on their own without treatment
  • Allows patients to avoid treatment side effects unless necessary
• Surgery
  • Complete removal of tumor with surrounding healthy tissue margin
  • High recurrence rates of 24 to 77 percent even after complete removal
  • Now primarily recommended for specific abdominal wall tumors that fail observation
  • Less favored due to risk of tumor return and potential for extensive operations
• Radiation Therapy
  • Uses high-energy beams to damage tumor cells and stop growth
  • Can be used after surgery, before surgery, or as primary treatment
  • Helpful for tumors near vital structures that cannot be safely removed
  • Carries long-term risk of causing other cancers years later
• Medical Therapies
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like sulindac or celecoxib to reduce inflammation
  • Antiestrogen medications like tamoxifen to block hormone-related growth signals
  • Chemotherapy combinations including doxorubicin, methotrexate, or vinblastine for aggressive tumors
  • Tyrosine kinase inhibitors like sorafenib and pazopanib that block specific growth signals
  • Nirogacestat, the first FDA-approved drug specifically for progressive desmoid tumors
• Ablation Techniques
  • Cryoablation using extreme cold to freeze and kill tumor cells
  • Radiofrequency ablation using heat from radio waves
  • High-intensity focused ultrasound using sound waves to destroy tissue
  • Alternative options to surgery or medical therapy for selected patients
• Pain Management
  • NSAIDs and other pain medications to control discomfort
  • Physical therapy to maintain function and reduce pain
  • Complementary approaches like acupuncture or mindfulness practices
  • Considered paramount for quality of life independent of tumor treatment